Fios Genomics contributed to breast cancer study for ESMO 2017

Our recent collaboration with Genentech, GEICAM and other institutions (see below) resulted in a poster presented at the last ESMO Congress in Madrid, Spain.

The main objective of the study was to describe the immune phenotype during breast cancer development which could support the development of patient-tailored therapies. For this reason, the study aimed to find differences in the gene expression pattern of immune-related genes.

Fios Genomics contributed to this project with a differential expression analysis using pairs of primary and metastatic samples from patients taking part in the GEICAM/2009-03 (ConvertHER) study. Our team used nanostring data and performed enrichment analysis using KEGG pathways. They compared changes in expression level between primary and metastatic tumours and generated bespoke plots for this project.

The ESMO 2017 Congress is in partnership with the European Association for Cancer Research (EACR).